<DOC>
	<DOCNO>NCT02780713</DOCNO>
	<brief_summary>This phase 1 open label single centre study AZD9496 administer orally healthy volunteer . The study design involve single administration different form , formulation dos AZD9496 . The study design investigate different AZD9496 variant . The study evaluate pharmacokinetic profile safety tolerability different form , formulation dose AZD9496 This fix sequence study 5-sequential treatment period healthy volunteer . Each volunteer receive 5 single dos AZD9496 different form , formulation dos .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Safety Different Forms Formulations AZD9496 Healthy Subjects</brief_title>
	<detailed_description>A phase 1 , open-label , single centre study ass pharmacokinetics , Safety tolerability different form , formulation dos AZD9496 healthy volunteer . This fixed sequence study 5-sequential treatment period . Each subject receive 5 single dos AZD9496 different form , formulation dos . - Treatment period one ass AZD9496 Variant A : 100mg . - Treatment period two ass AZD9496 Reference form : 100mg . - Treatment period 3 ass one AZD9496 Variants , B , C D : 100mg . - Treatment period 4 ass one AZD9496 Variants , B , C D : 100mg . - Treatment period 5 ass one AZD9496 Variants A , B , C D : *300mg . *Based review pharmacokinetic safety result Treatment Periods 1 , 3 4 , low dose 200 mg may administer Treatment Period 5 .</detailed_description>
	<criteria>1 . Provision sign date , write informed consent prior study specific procedure . 2 . Healthy male and/or female subject age 18 65 year suitable vein cannulation repeat venipuncture . 3 . Females must negative pregnancy test screen admission unit , must lactate must nonchildbearing potential , confirm screen fulfil 1 follow criterion : Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment FSH level postmenopausal range ( OR ) Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy bilateral salpingectomy , tubal ligation 4 . Male subject age 18 39 year must vasectomize . Male subject age 40 65 year must either vasectomize intention father child period 6 month receive last dose IMP . 5 . Have body mass index ( BMI ) 18.0 32.0 kg/m2 , inclusive , weigh least 50 kg 100 kg , inclusive . 6 . Values AST , ALT , TBL , GGT ALP must upper limit normal range screen . 1 . History clinically significant disease disorder , opinion investigator , may either put subject risk participation study , influence result subject 's ability participate study . 2 . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . 3 . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration IMP . 4 . Previous history venous arterial thromboembolism thrombophilia . 5 . History endometrial polyp , endometrial cancer , atypical endometrial hyperplasia , endometrial disorder unless subject undergone total hysterectomy evidence active disease ( female ) . 6 . Any clinically significant abnormality clinical chemistry ( Inclusion no.6 ) , hematology , urinalysis result screen , judge investigator . 7 . Any clinically significant abnormal finding supine vital sign , 10 minute supine rest , screen and/or admission unit , define : ( ) Systolic blood pressure &lt; 90 mmHg ≥ 150 mmHg ( b ) Diastolic blood pressure &lt; 50 mmHg ≥ 95 mmHg ( c ) Heart rate &lt; 45 &gt; 90 beat per minute 8 . Any clinically important abnormality rhythm , conduction morphology rest 12lead ECG , judge investigator , may interfere interpretation QTc interval change , include abnormal STTwave morphology pronounce leave ventricular hypertrophy . 9 . Prolonged QTcF &gt; 460 m female QTcF &gt; 450 m male family history long QT syndrome . 10 . PR ( PQ ) interval shorten &lt; 110 ms evidence ventricular preexcitation ) . 11 . PR ( PQ ) interval prolongation &gt; 240 m , intermittent second ( Wenckebach block asleep exclusive ) third degree AV block . 12 . Persistent intermittent complete bundle branch block QRS &gt; 120 m evidence pronounce ventricular hypertrophy preexcitation . 13 . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) antibody . 14 . Known suspected history drug abuse , judge investigator . 15 . Current smoker smoke used nicotine product within 3 month prior screen . 16 . Known suspected history alcohol drug abuse excessive intake alcohol , judge investigator . 17 . Positive screen drug abuse , alcohol cotinine screen admission unit . 18 . History severe allergy/hypersensitivity ongoing allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD9496 . 19 . Excessive intake caffeine/xanthine contain drink food ( e.g. , coffee , tea , chocolate ) , judge investigator . 20 . Use drug enzymeinducing property St John 's Wort within 3 week prior first administration IMP . 21 . Use prescribed nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior first administration IMP long medication long halflife Note : Hormonal replacement therapy allow female . 22 . Plasma donation within 1 month screen blood donation/loss 500 mL 3 month prior screen 23 . Has receive another new chemical entity ( define compound approve marketing ) within 3 month first administration IMP study . The period exclusion 3 month final dose previous study 1 month last visit previous study , whichever long . ote : Subjects consent screen , dose study previous phase I study , exclude . 24 . Involvement AstraZeneca , PAREXEL study site employee close relatives 25 . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . 26 . Subjects vegans medical dietary restriction . 27 . Subjects communicate reliably investigator . 28 . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>AZD9496</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>